Industry News (Funding)

SBIR Phase II Grants Received To Develop Anti-Infectives

Published in TB and Outbreaks Week, June 10th, 1996

Cubist Pharmaceuticals, Inc., Cambridge, Massachusetts, was awarded two separate Small Business Innovation Research (SBIR) Phase II grants to develop antimicrobial agents to treat pneumonia caused by Pneumocystis carinii and to treat Mycobacterium tuberculosis infections.

The grants, totaling $1.3 million over two years, are for the use of further development of the company's proprietary drug discovery technology and for the identification of specific small molecule drug candidates to treat and control these two highly pathogenic microorganisms.

The SBIR grants are funded by the U.S. Small Business Administration and administered by the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (1996-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry